Eventide Asset Management LLC Takes $1.16 Million Position in Inventiva S.A. Sponsored ADR $IVA

Eventide Asset Management LLC acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 250,000 shares of the company’s stock, valued at approximately $1,155,000. Eventide Asset Management LLC owned approximately 0.17% of Inventiva as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Creative Planning purchased a new position in shares of Inventiva in the second quarter valued at about $32,000. Cerity Partners LLC purchased a new position in shares of Inventiva in the fourth quarter valued at about $93,000. NewEdge Advisors LLC purchased a new position in shares of Inventiva in the third quarter valued at about $116,000. Commonwealth Equity Services LLC lifted its position in shares of Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after acquiring an additional 12,704 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Inventiva in the third quarter valued at about $649,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Price Performance

Shares of IVA stock opened at $3.85 on Monday. Inventiva S.A. Sponsored ADR has a 12-month low of $2.85 and a 12-month high of $7.98. The stock’s 50-day moving average price is $5.07 and its 200-day moving average price is $5.40.

Inventiva (NASDAQ:IVA) last issued its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million during the quarter. Equities research analysts predict that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Truist Financial started coverage on Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $16.56.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.